Compare CCO & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCO | VALN |
|---|---|---|
| Founded | 1995 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 820.0M |
| IPO Year | 2005 | 2021 |
| Metric | CCO | VALN |
|---|---|---|
| Price | $2.08 | $8.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $2.10 | ★ $15.75 |
| AVG Volume (30 Days) | ★ 2.2M | 21.0K |
| Earning Date | 11-06-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,569,344,000.00 | $211,089,992.00 |
| Revenue This Year | $6.76 | $5.08 |
| Revenue Next Year | $4.42 | $12.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 54.21 | 13.48 |
| 52 Week Low | $0.81 | $3.62 |
| 52 Week High | $2.09 | $12.25 |
| Indicator | CCO | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 64.60 | 34.74 |
| Support Level | $2.00 | $8.62 |
| Resistance Level | $2.09 | $9.10 |
| Average True Range (ATR) | 0.07 | 0.25 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 90.63 | 0.00 |
Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.